

Abstract of the Disclosure

5 The subject invention provides pharmaceutical compounds useful in the
treatment of Type II diabetes. These compounds are advantageous because they are
readily metabolized by the metabolic drug detoxification systems. Particularly,
thiazolidinedione analogs that have been designed to include esters within the
structure of the compounds are provided. This invention is also drawn to methods of
treating disorders, such as diabetes, comprising the administration of therapeutically
10 effective compositions comprising compounds that have been designed to be
metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical
compositions of the ester-containing thiazolidinedione analogs are also taught.